Supporting Information

for

One-pot synthesis of enantiomerically pure *N*protected allylic amines from *N*-protected αamino esters

Gastón Silveira-Dorta, Sergio J. Álvarez-Méndez, Víctor S. Martín, José M. Padrón*

Address: Instituto Universitario de Bio-Orgánica "Antonio González" (IUBO-AG), Centro de Investigaciones Biomédicas de Canarias (CIBICAN), Universidad de

La Laguna. C/ Astrofísico Francisco Sánchez 2, 38206, La Laguna, Spain

Email: José M. Padrón - jmpadron@ull.es

*Corresponding author

General procedures, analytical data and spectra of all compounds, methods for conversion

Table of Contents

General	S3
General procedures	S3
Compound characterization data	S5
Figure S1: ¹ H and ¹³ C NMR spectra for compound 1	S9

Figure S2: ¹ H and ¹³ C NMR spectra for compound 2a	S10
Figure S3: ¹ H and ¹³ C NMR spectra for compound 2b	S11
Figure S4: ¹ H and ¹³ C NMR spectra for compound 2c	S12
Figure S5: ¹ H and ¹³ C NMR spectra for compound (<i>E</i>)-2d	S13
Figure S6: ¹ H and ¹³ C NMR spectra for compound (<i>Z</i>)-2d	S14
Figure S7: ¹ H and ¹³ C NMR spectra for compound 2e	S15
Figure S8: ¹ H and ¹³ C NMR spectra for compound 2f	S16
Figure S9: ¹ H and ¹³ C NMR spectra for compound 2g	S17
Figure S10: ¹ H and ¹³ C NMR spectra for compound 3	S18
Figure S11: ¹ H and ¹³ C NMR spectra for compound 4a	S19
Figure S12: ¹ H and ¹³ C NMR spectra for compound 4b	S20
Figure S13: ¹ H and ¹³ C NMR spectra for compound 4c	S21
Figure S14: ¹ H and ¹³ C NMR spectra for compound 5	S22
Figure S15: ¹ H and ¹³ C NMR spectra for compound 6a	S23
Figure S16: ¹ H and ¹³ C NMR spectra for compound 6b	S24
Figure S17: HPLC analysis of rac-2a and 2a	S25
Table S1: ¹ H NMR data comparison with literature data for 2a	S27
Table S2: ¹³ C NMR data comparison with literature data for 2a	S27
Table S3: ¹ H NMR data comparison with literature data for 2b	S28
Table S4: ¹³ C NMR data comparison with literature data for 2b	S28
Table S5: ¹ H NMR data comparison with literature data for (E)-2d	S29
Table S6: ¹³ C NMR data comparison with literature data for (E)-2d	S29
Table S7: ¹ H NMR data comparison with literature data for (Z)-2d	S30
Table S8: ¹³ C NMR data comparison with literature data for (Z)-2d	S30
Table S9: ¹ H NMR data comparison with literature data for 4c	S31
Table S10: ¹³ C NMR data comparison with literature data for 4c	S32
References	S33

S2

General

¹H NMR spectra were recorded at 400 and 500 MHz at 298 K, ¹³C NMR spectra were recorded at 100 and 125 MHz, respectively. Chemical shifts were reported in units (ppm) by assigning TMS resonance in the ¹H NMR spectrum as 0.00 ppm (CDCl₃, 7.26 ppm). Data were reported as follows: chemical shift, multiplicity (s = singlet, d = doublet, t = triplet, q = quartet, quin = quintuplet, sex = sextet, dd = double doublet, ddd = double double doublet, m = multiplet and br = broad), coupling constant (J values) in Hz and integration. Chemical shifts for ¹³C NMR spectra were recorded in ppm from tetramethylsilane as the internal standard using the central peak of CDCl₃ (77.0 ppm). Reagent-grade chemicals were obtained from diverse commercial suppliers and were used as received. A freshly opened bottle of diisobutylaluminium hydride was used. Optical rotations were measured with a polarimeter at the sodium line at different temperatures in CHCI₃. Accurate masses (HRMS) were determined by electrospray ionization (ESI-TOF) and electron impact (EI-TOF). Reactions were monitored using thin-layer chromatography (TLC) on aluminum packed percolated Silica Gel 60 F₂₅₄ plates. Flash column chromatography was carried out with silica gel 60 (particle size less than 0.020 mm) by using appropriate mixtures of ethyl acetate and hexanes, or diethyl ether and hexanes as eluents. Compounds were visualized by use of UV light and 2.5% phosphomolybdic acid in ethanol. Reactions were performed using oven-dried glassware. All reactions involving air- or moisture-sensitive materials were carried out under argon atmosphere. Anhydrous magnesium sulfate was used for drying solutions. Chemical nomenclature was generated using ChemBioDraw Ultra 13.0.

General procedures

General procedure A: preparation of N-protected allylic amines

To a solution of (*S*)-methyl 2-(dibenzylamino)propanoate (**1**, 1 mmol) in dry toluene (3 mL) was added dropwise DIBAL-H (1.0 M solution in hexanes, 1 mmol) at -78 °C. After stirring for 2 h at -78 °C, the appropriate organophosphorus reagent was added in small portions (or dropwise) at -78 °C (some of them required to be prepared separately, see below). The mixture was allowed to warm gradually to 0 °C. Then, the mixture was quenched with saturated Rochelle's salt solution (10 mL). The reaction mixture was vigorously stirred for 2 h at rt. After dilution with water (10 mL), the biphasic mixture was separated and extracted with Et₂O (3 × 10 mL). The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuum. The residue was purified by flash chromatography on silica gel (eluent EtOAc/hexanes) to give the corresponding *N*-protected allylic amine.

General procedure B: preparation of N-protected β -hydroxy allylic amines

To a solution of (*S*)-benzyl 2-(dibenzylamino)-3-hydroxypropanoate (**3**) or (2S,3R)-ethyl 2-(dibenzylamino)-3-hydroxybutanoate (**5**) (0.27 mmol) in dry toluene (3 mL) was added DIBAL-H in two portions, first dropwise at -78 °C (0.41 mL, 1.0 M solution in hexanes, 0.41 mmol) and the rest 1 h later (0.14 mL, 1.0 M solution in hexanes, 0.41 mmol). After stirring for 2 h at -78 °C, the appropriate organophosphorus reagent was carefully added at -78 °C (some of them were prepared separately, see below). The mixture was allowed to warm gradually to 0 °C. Then, the mixture was quenched with saturated Rochelle's salt solution (10 mL). The reaction mixture was vigorously stirred for 2 h at rt. After dilution with water (10 mL), the biphasic mixture was separated and extracted with Et₂O (3 × 10 mL). The combined organic phases were washed with brine, dried over MgSO₄, filtered and concentrated in vacuum. The residue was purified by flash chromatography on silica gel (eluent EtOAc/hexanes) to give the corresponding *N*-protected β -hydroxy allylic amine.

General procedure C: preparation of Wittig organophosphorus reagents

To a stirred suspension of the appropriate phosphonium bromide (1.0 mmol) in dry toluene (10 mL) was added dropwise $KN(TMS)_2$ (1 mL, 0.5 M solution in toluene, 1.0 mmol) at 0 °C. After 30 min the flask was cooled to -78 °C.

General procedure D: preparation of HWE organophosphorus reagents

To a solution of the appropriate phosphonate (0.5 mmol) in dry toluene (2 mL) at 0 $^{\circ}$ C, was added carefully NaH (60% in mineral oil, 0.5 mmol). The mixture was stirred for 4 h at 0 $^{\circ}$ C.

General procedure E: preparation of Still–Gennari organophosphorus reagents

To freshly distilled THF (20 mL) was added $KN(TMS)_2$ (2 mL, 0.5 M in THF, 1 mmol) and 18-crown-6 (280 mg, 1.1 mmol). The reaction mixture was cooled to -78 °C and a solution of the appropriate phosphonate (1.0 mmol) in 10 mL of dry THF was added via cannula. The reaction was stirred 30 min at -78 °C and then 1 h at 0 °C. Then, the mixture was cooled to -78 °C.

Compound characterization data

(S,E)-Ethyl 4-(dibenzylamino)pent-2-enoate (2a) [1]

The general procedure A was applied to **1** on a 0.35 mmol (100 mg) scale using ethyl 2-(triphenylphosphoranylidene)acetate (261 mg, 0.51 mmol), to give after purification (eluent Et₂O/hexanes 15:85) **2a** (80.3 mg, 71%, *E/Z* >20:1) as a colorless oil. $[\alpha]^{25}_{D} = -136.0$ (*c*, 1.00, CHCl₃).

(S,Z/E)-N,N-Dibenzyl-4-phenylbut-3-en-2-amine (2b) [2]

The general procedure A was applied to **1** on a 0.35 mmol (100 mg) scale using the ylide of benzyltriphenylphosphonium bromide (303.3 g, 0.7 mmol) prepared according to the general procedure C, to give after purification (eluent Et₂O/hexanes 1/99) **2b** (68 mg, 60%, E/Z = 1/1.3) as a colorless oil inseparable mixture of E/Z isomers.

(S,Z)-N,N-dibenzyloctadec-3-en-2-amine (**2c**)

The general procedure A was applied to **1** on a 0.35 mmol (100 mg) scale using the ylide of tetradecyltriphenylphosphonium bromide (387.5 mg, 0.7 mmol) prepared according to the general procedure C, to give after purification (eluent Et₂O/hexanes 5/95) **2c** (59 mg, 40%, *E/Z* = 1/20) as a colorless oil. $[\alpha]^{25}_{D}$ = +12.4 (*c*, 1.13, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): δ = 0.77 (t, *J* = 7.1 Hz, 3H), 1.04 (d, *J* = 7.1 Hz, 4H), 1.06-1.19 (m, 23H), 1.63-1.76 (m, 2H), 3.31 (AB System, *J* = 14.0 Hz, 2H), 3.46 (ABX System, *J* = 13.7, 6.8 Hz, 1H), 3.62 (AB System, *J* = 14.0 Hz, 2H), 5.29-5.44 (m, 2H), 7.07-7.27 (m, 10H) ppm. ¹³C-NMR (125 MHz, CDCl₃): δ = 166.9, 150.5, 139.9, 128.6, 128.5, 128.3, 128.2, 126.9, 121.5, 53.8, 51.5, 14.2 ppm. HRMS (ESI-TOF) (m/z) [M + H⁺] = calcd for C₃₂H₅₀N 448.3943, found 448.3949.

(S,Z/E)-4-(Dibenzylamino)pent-2-enenitrile (2d) [3-4]

The general procedure A was applied to **1** on a 0.35 mmol (100 mg) using (triphenylphosphoranylidene)acetonitrile (154 mg, 1.51 mmol), to give after purification (eluent Et₂O/hexanes 15/85) **2d** (100 mg, 72%, E/Z = 5/1) as a colorless oil. (*E* isomer) [α]²⁵_D = -150.2 (*c*, 1.5, CHCl₃).

Ethyl (S,E)-4-(dibenzylamino)-2-methylpent-2-enoate (2e)

The general procedure A was applied to **1** on a 0.35 mmol (100 mg) scale using ethyl 2-(triphenylphosphoranylidene)propanoate (187 mg, 0.51 mmol), to give after purification (eluent Et₂O/hexanes 15/85) **2e** (89.3 mg, 71%, *E*/*Z* = 20/1) as a colorless oil. $[\alpha]_{D}^{25}$ = -63.4 (*c*, 1.02, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): δ =

1.26 (d, J = 16.0 Hz, 3H), 1.37 (t, J = 6.6 Hz, 3H), 1.70 (s, 3H), 3.25 (AB System, J = 14.0 Hz, 2H), 3.66-3.69 (m, 1H), 3.83 (AB System, J = 14.0 Hz, 2H), 4.27 (ABX System, J = 7.1, 1.7 Hz, 2H), 6.90 (dd, J = 9.6, 1.2 Hz, 1H), 7.25-7.44 (m, 10H) ppm. ¹³C-NMR (125 MHz, CDCl₃): $\delta = 168.1$, 141.8, 140.2, 128.7, 128.6, 128.3, 126.8, 60.7, 54.0, 51.6, 17.3, 14.3, 12.8 ppm. HRMS (ESI-TOF) (m/z) [M + H⁺] = calcd for C₂₂H₂₈NO₂ 338.2120, found 338.2120.

(S,E)-Methyl 4-(dibenzylamino)pent-2-enoate (2f)

The general procedure A was applied to **1** on a 0.35 mmol (100 mg) scale using the ylide of methyl 2-(dimethylylphosphoryl)propanoate (171.0 mg, 0.51 mmol) prepared according to the general procedure D, to give after purification (eluent Et₂O/hexanes 15/85) **2f** (70 mg, 68%, *E/Z* = 1/20) as a colorless oil. $[\alpha]^{25}{}_{D}$ = -116.6 (*c*, 0.99, CHCl₃); ¹H-NMR (500 MHz, CDCl₃, 25 °C): δ = 1.26 (d, *J* = 6.8 Hz, 3H), 3.50 (app. quint, *J* = 6.3 Hz, 1H), 3.64 (AB System, *J* = 13.9 Hz, 4H), 3.78 (s, 3H), 5.96 (dd, *J* = 15.9, 1.3 Hz, 1H), 7.11 (dd, 15.9, 6.0 Hz, 1H), 7.24-7.42 (m, 10H) ppm. ¹³C-NMR (125 MHz, CDCl₃): δ = 166.9, 150.6, 139.9, 128.6, 128.5, 128.3, 128.2, 126.9, 121.5, 51.7, 51.5, 14.2 ppm. HRMS (ESI-TOF) (m/z) [M + H⁺] = calcd for C₂₀H₂₄NO₂ 310.1807, found 310.1811.

(S,Z)-Ethyl 4-(dibenzylamino)pent-2-enoate (2g)

The general procedure A was applied to **1** on a 0.35 mmol (100 mg) scale using the ylide of ethyl 2-(bis(2,2,2-trifluoroacetyl)phosphoryl)acetate (0.2 mL, 1.0 mmol) prepared according to the general procedure E, to give after purification (eluent Et₂O/hexanes 15/85) **2g** (100 mg, 78%, *E/Z* = 1/1.6) as a colorless oil. $[\alpha]^{25}{}_{D}$ = +99.3 (*c*, 1.28, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): δ = 1.13 (d, *J* = 7.1 Hz, 3H), 3.37 (AB System, *J* = 14.2 Hz, 2H), 3.42 (s, 3H), 3.70 (AB System, *J* = 14.2 Hz, 2H), 4.34-4.40 (m, 1H), 5.75 (dd, *J* = 11.8, 0.6 Hz, 1H), 6.20 (dd, *J* = 11.8, 9.7 Hz, 1H), 7.07-7.26 (m, 10H) ppm. ¹³C-NMR (125 MHz, CDCl₃): δ = 166.3, 149.4, 140.1, 128.5, 128.4, 128.3, 128.1, 126.7, 120.3, 54.1, 52.2, 51.0, 18.1 ppm.

(R,E)-Ethyl 4-(dibenzylamino)-5-hydroxypent-2-enoate (4a)

The general procedure B was applied to **3** on a 0.26 mmol (113 mg) scale using ethyl 2-(triphenylphosphoranylidene)acetate (141 mg, 0.41 mmol), to give after purification eluent AcEOt/hexanes 1/9) **4a** (89.3 mg, 65%, *E/Z* >20/1) as a colorless oil. $[\alpha]^{25}{}_{D}$ = -116.0 (*c*, 1.07, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): δ = 1.37 (t, *J* = 6.9 Hz, 3H), 2.88 (br, 1H), 3.45-3.52 (m, 3H), 3.74-3.79 (m, 1H) 3.95 (AB System, *J* = 12.9 Hz, 2H), 2.80 (q, *J* = 7.1 Hz, 2H), 5.98 (d, *J* = 15.9, 1H), 7.02 (dd, *J* = 7.8 Hz, 1H), 7.29-7.40 (m, 11H) ppm. ¹³C-NMR (125 MHz, CDCl₃): δ = 165.7, 142.2, 138.5, 128.9, 128.8, 128.7, 128.6, 128.5, 127.5, 125.9, 60.8,

60.4, 53.8, 14.3 ppm. HRMS (ESI-TOF) (m/z) $[M + H^+] = \text{calcd for } C_{21}H_{26}NO_3$ 339.1834, found 339.1836.

(*R*,*E*)-Methyl 4-(dibenzylamino)-5-hydroxypent-2-enoate (**4b**)

The general procedure B was applied to **3** on a 0.26 mmol (113 mg) scale using the ylide of methyl 2-(dimethylylphosphoryl)propanoate (180.6 mg, 0.54 mmol) prepared according to the general procedure D, to give after purification (eluent EtOAc/hexanes 10/90) **4b** (44 mg, 50%, *E/Z* > 20/1) as a colorless oil. $[\alpha]^{25}_{D} = -103.6$ (*c*, 1.03, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): $\delta = 2.20$ (s, 3H), 3.64-3.68 (m, 1H), 3.70 (AB System, *J* = 13.8 Hz, 2H), 3.80 (AB System, *J* = 13.8, 2H), 4.42 (dd, *J* = 11.7, 5.6 Hz, 1H), 4.61 (ABX System, *J* = 5.7, 0.9 Hz, 1H), 6.16 (dd, *J* = 9.9, 1.8 Hz, 1H), 6.93 (dd, *J* = 9.9, 1H), 7.29-7.38 (m, 10H) ppm. ¹³C-NMR (125 MHz, CDCl₃): $\delta = 166.1$, 146.3, 138.7, 128.6, 128.5, 127.5, 123.1, 67.2, 54.5, 50.3 ppm. HRMS (ESI-TOF) (m/z) [M + H⁺] = calcd for C₂₀H₂₄NO₃ 326.1756, found 326.1756.

(R,Z)-2-(Dibenzylamino)octadec-3-en-1-ol (4c)

The general procedure B was applied to **3** on a 0.26 mmol (113 mg) scale using the ylide of tetradecyltriphenylphosphonium bromide (387.5 mg, 0.7 mmol) prepared according to the general procedure C, to give after purification (eluent EtOAc/hexanes 5/95) **4c** (70.5 mg, 60%, E/Z = 37/63) as a colorless oil. HRMS (ESI-TOF) (m/z) [M + H⁺] = calcd for C₃₂H₅₀NO 464.3892, found 464.3890.

(4R,5R,E)-Ethyl 4-(dibenzylamino)-5-hydroxyhex-2-enoate (6a)

The general procedure B was applied to **5** on a 0.26 mmol (120 mg) scale using ethyl 2-(triphenylphosphoranylidene)acetate (141 mg, 0.41 mmol), to give after purification (eluent AcEOt/hexanes 10/90) **6a** (37mg, 40%, *E/Z* > 20/1) as a colorless oil. $[\alpha]^{25}{}_{D}$ = -137.2 (*c* 1.05, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): δ = 1.03 (d, *J* = 6.1 Hz, 3H), 1.39 (t, *J* = 7.2 Hz, 3H), 2.92 (t, *J* = 9.9 Hz, 1H), 3.35 (AB System, *J* = 13.3 Hz, 2H), 3.91-3.96 (m, 1H), 4.00 (AB System, *J* = 13.3 Hz, 2H), 4.30 (q, *J* = 7.1 Hz, 2H), 5.91 (d, *J* = 15.8 Hz, 1H), 6.90 (dd, *J* = 15.7, 10.2 Hz, 1H), 7.28-7.38 (m, 10H) ppm. ¹³C-NMR (125 MHz, CDCl₃): δ = 165.4, 141.8, 138.3, 128.9, 128.7, 127.5, 127.4, 66.8, 64.4, 60.8, 53.9, 19.6, 14.3 ppm. HRMS (ESI-TOF) (m/z) [M + H⁺] = calcd for C₂₂H₂₈NO₃ 354.2069, found 354.2068.

(4R,5R,E)-Ethyl 4-(dibenzylamino)-5-hydroxy-2-methylhex-2-enoate (6b)

The general procedure B was applied to **5** on a 0.26 mmol (120 mg) scale using ethyl 2-(triphenylphosphoranylidene)propanoate (140 mg, 0.41 mmol). The

residue was purified by flash chromatography on silica gel (eluent AcEOt/hexanes 10/90), to afford **6b** (37 mg, 39%, *E/Z* > 20/1) as a colorless oil. $[\alpha]^{25}{}_{D} = -90.4$ (*c* 1.14, CHCl₃); ¹H-NMR (500 MHz, CDCl₃): $\delta = 1.07$ (d, *J* = 6.1 Hz, 3H), 1.39 (t, *J* = 7.1 Hz, 3H), 1.83 (d, *J* = 1.3 Hz, 3H), 3.25 (dd, *J* = 10.8, 9.7 Hz, 1H), 3.36 (AB System, *J* = 13.4 Hz, 2H), 3.87-3.93 (m, 1H), 4.03 (AB System, *J* = 13.4 Hz, 2H), 4.23 (br, 1H), 4.30 (q, *J* = 7.0 Hz, 2H), 6.82 (dd, *J* = 10.9, 1.4 Hz, 1H), 7.27-7.37 (m, 10H) ppm. ¹³C-NMR (125 MHz, CDCl₃): $\delta = 167.4$, 138.6, 134.9, 134.1, 128.8, 128.6, 127.4, 65.3, 63.7, 61.0, 54.1, 30.3, 19.2, 14.3, 13.8 ppm. HRMS (ESI-TOF) (m/z) [M + H⁺] = calcd for C₂₃H₃₀NO₃ 368.2226, found 368.2227.



Figure S1: 1 H (500 MHz) and 13 C (125 MHz) NMR spectra of 1a in CDCl₃.



Figure S2: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 2a in CDCl₃.





Figure S4: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 2c in CDCl₃.



Figure S5: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of (*E*)-2d in CDCl₃.



Figure S6: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of (*Z*)-2d in CDCl₃.



Figure S7: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of **2e** in CDCl₃.



Figure S8: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 2f in CDCl₃.



Figure S9: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 2g in CDCl₃.



Figure S10: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of **3** in CDCl₃.

Figure S11: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 4a in CDCl₃.







Figure S13: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 4c in CDCl₃.



Figure S14: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 5 in CDCl₃.



Figure S15: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of **6a** in CDCl₃.



Figure S16: ¹H (500 MHz) and ¹³C (125 MHz) NMR spectra of 6b in CDCl₃.



Retention time	% Area
10.79	52
13.13	48



Figure S17: HPLC analysis of *rac-2a* and *2a*. Chiral The enantiomeric ratio was determined by HPLC analysis in comparison with racemic material (CHIRALCEL OD-H column, 95/5 *n*-hexane/2-propanol, 0.5 mL/min, major isomer: $t_R = 10.79$ min, enantiomer of *2a* 13.13 min. detection at 210.0 nm, 25 °C).

NMR data comparison with literature data



2a

Table S1: ¹H NMR data (CDCI₃) comparison with literature data for 2a.

This work	Ref. 1
500 MHz	300 MHz
1.25 (d, <i>J</i> = 7.0Hz, 3H)	1.26 (d, <i>J</i> = 6.8 Hz, 3H)
1.34 (t, <i>J</i> = 7.0 Hz, 3H)	1.34 (t, <i>J</i> = 7.1 Hz, 3H)
3.47–3.53 (m, 1H)	3.58–3.48 (m, 1 H)
3.63 (AB system, <i>J</i> _{AB} = 13.9Hz, 4H)	3.60 (d, <i>J</i> = 13.9 Hz, 2H)
	3.67 (d, <i>J</i> = 13.9 Hz, 2H)
4.24 (q, <i>J</i> = 7.1 Hz, 2H)	4.24 (q, <i>J</i> = 7.1 Hz, 2 H)
5.93 (dd, <i>J</i> = 15.8, 1.6 Hz, 1H)	5.94 (dd, <i>J</i> = 15.9, 1.6 Hz, 1H)
7.09 (dd, <i>J</i> = 15.8, 6.0 Hz, 1H)	7.10 (dd, <i>J</i> = 15.9, 6.0 Hz, 1H)
7-23-7.42 (m, 10H)	7.35–7.11 (m, 10H)

 Table S2: ¹³C NMR data (CDCl₃) comparison with literature data for 2a.

This work	Ref. 1
125 MHz	75 MHz
14.1	14.0
14.3	14.2
	53.6
53.8 x2	53.6
60.4	60.3
121.9	121.8
126.9	126.8
	128.0
128.3x2	128.2
128.5 x2	128.4
139.9	139.8
150.2	150.2
166.5	166.4



2b

Table S3: ¹H NMR data (CDCl₃) comparison with literature data for 2b.

This work 500 MHz (inseparable mixture)	Ref. 2 (<i>E</i> isomer) 200 MHz
1.34 (d, <i>J</i> = 6.9 Hz, 3H)	1.36 (d, <i>J</i> = 6.7 Hz, 3H)
3.57-3.52 (apparent quint, <i>J</i> = 6.7 Hz 1H)	3.62-3.52 (m, 1H)
3.66 (AB system, <i>J</i> = 13.9 Hz, 2H)	3.66 (d, <i>J</i> = 13.9 Hz, 2H)
3.77 (AB system, <i>J</i> = 13.9 Hz, 2H)	3.79 (d, <i>J</i> = 13.9 Hz, 2H)
6.38 (dd, <i>J</i> = 16.1, 6.6 Hz, 1H)	6.38 (dd, <i>J</i> = 16.1, 6.3 Hz, 1 H)
6.52 (d, J = 16.1 Hz, 1H)	6.52 (d, <i>J</i> = 16.1 Hz, 1 H)
7.43-7.24 (m, 15H)	7.43-7.24 (m, 15 H)

Table S4: ¹³C NMR data (CDCI_{I3}) comparison with literature data for 2b.

This work (<i>E</i> isomer)	This work (Zisomer)	Ref. 2 (<i>E</i> isomer)
125 MHz	125 MHz	50 MHz
15.9	18.3	15.7
53.7	53.8	53.6
54.9	50.5	54.8
126.3	126.3	126.2
126.6	126.5	126.6
127.3	126.7	127.1
128.1	128.0	128.1
128.6	128.2	128.4,
128.7	128.8	128.7
130.9	131.0	130.9
131.7	132.8	131.6
140.4	137.3	140.5 x 2
140.6	140.6	141.1



(*E*)-2d

Table S5: ¹H NMR data (CDCl₃) comparison with literature data for (*E*)-2d.

This work 500 MHz	Ref. 3 300 MHz	Ref. 4 300 MHz
1.25 (d. <i>J</i> =6.9 Hz. 3H)	1.21 (d. J = 6.9 Hz. 3H)	1.21 (d. <i>J</i> =6.9 Hz. 3H)
3.50 (m, 1H)	3.50 (m. 1H)	3.50 (m. 1H)
3.62 (s, 4H)	3.58 (s, 4H)	3.58 (s, 4H)
5.51 (dd, J = 16.4, 1.7 Hz,	5.48 (d, J = 16.5 Hz, 1H)	5.48 (d, J=16.5 Hz, 1H)
1H)		
6.82 (dd, <i>J</i> = 16.4, 5.3 Hz,	6.78 (dd, <i>J</i> = 16.5, 5.3 Hz,	6.78 (dd, <i>J</i> =16.5, 5.3 Hz,
1H)	1H)	1H)
7.26-7.39 (m, 10H)	7.22-7.37 ppm (m, 10H)	7.22–7.37 (m, 10H)

 Table S6: ¹³C NMR data (CDCl₃) comparison with literature data for (*E*)-2d.

This work	Ref. 3	Ref 4
125 MHz	75 MHz	75 MHz
13.2	13.1	13.1
53.8	53.7	53.7
54.5	54.4	54.4
100.3	100.1	100.1
117.4	117.4	117.4
127.2	127.1	127.1
128.4	128.3	128.3
128.5	128.4	128.4
139.2	139.2	139.2
157.4	157.4	157.4



Table S7: ¹H NMR data (CDCl₃) comparison with literature data for **(Z)-2d**.

This work	Ref. 3	Ref. 4
500 MHz	300 MHz	300 MHz
1.23 (d, <i>J</i> = 6.7 Hz, 3H)	1.29 (d, <i>J</i> = 6.9 Hz, 3H)	1.29 (d, <i>J</i> = 6.9 Hz, 3H)
3.44 and 3.70 (2xd, <i>J</i> = 13.8 Hz, 4H)	3.52 and 3.77 (2xd, <i>J</i> = 14.4	3.52 and 3.77 (2xd, J =
	Hz, 4H)	14.4 Hz, 4H)
3.76-3.77 (m, 1H)		
5.34 (d, <i>J</i> = 11.1 Hz, 1H),	5.41 (d, <i>J</i> = 11.2 Hz, 1H),	5.41 (d, <i>J</i> = 11.2 Hz, 1H),
6.47 (m, 1H)	6.54 (m, 1H)	6.54 (m, 1H)
7.14-7.28 (m, 10H)	7.22-7.37 (m, 10H)	7.22-7.37 (m, 10H)

Table S8: ¹³C NMR data (CDCl₃) comparison with literature data for (*Z*)-2d.

This work	Ref. 3	Ref. 4
125 MHz	75 MHz	75 MHz
17.4	17.4	17.4
54.3	54.2	54.2
55.4	55.3	55.3
100.1	100.2	100.2
117.3	117.4	117.4
127.1	127.2	127.2
128.3	128.3	128.3
128.6	128.4	128.4
139.3	139.3	139.3
155.5	155.5	155.5



Table S9: ¹H NMR data (CDCI₃) comparison with literature data for 4c.

This work	Ref. 5 (Zisomer)
500 MHz (inseparable mixture)	400 MHz
0.87 (app t, <i>J</i> = 6.9 Hz, 3H)	0.90 (app t, <i>J</i> = 6.8 Hz, 3H,)
1.25-1.30 (m, 24 H)	1.19−1.45 (m, 24H)
1.86-1.99 (m, 2H)	1.87-2.04 (m, 2H)
3.14 (br, 1H)	
3.33 (dd, <i>J</i> = 10.4, 5.2 Hz, 1H)	3.33 (dd, <i>J</i> = 10.4, 5.2, Hz, 1H)
3.36 (AB system, J = 13.5 Hz, 2H)	3.36 (d, <i>J</i> = 13.5 Hz, 2H)
3.58 (app t, <i>J</i> = 10.4 Hz, 1H)	3.60 (app t, <i>J</i> = 10.4 Hz, 1H)
3.63–3.69 (app td, <i>J</i> = 10.1, 5.2 Hz, 1H)	3.65−3.73 (app td, <i>J</i> = 10.1, 5.2 Hz,
	1H)
3.89 (AB system, <i>J</i> = 13.5 Hz, 2H))	3.91 (d, <i>J</i> = 13.5, Hz, 2H)
5.38-5.42 (m, 1H)	5.38-5.46 (m, 1H)
5.78 (app dt, <i>J</i> = 11.0, 7.5 Hz, 1H)	5.80 (app dt, <i>J</i> = 11.0, 7.5 Hz, 1H)
7.23-7.31 (m, 10H)	7.23-7.35 (m, 10H)

This work	Ref. 5 (Zisomer)
125 MHz (inseparable mixture)	100 MHz
14.1	14.1
22.7	22.7
28.1	28.1
29.18	
29.32	
29.37	29.37
29.48	29.39
29.52	29.5
29.63	29.6
29.67	29.66
29.95	29.70
31.9	30.0
32.8	31.9
53.4	53.5
53.5	
56.8	56.8
61.1	
61.2	61.2
122.1	122.1
122.8	
127.2	127.2
128.5	128.5
128.8	128.8
129.0	
137.3	137.3
137.9	
139.2	
139.3	139.3

Table S10: ¹³C NMR data (CDCI₃) comparison with literature data for 4c.

REFERENCES

[1] Concellón, J. M.; Méjica, C. Eur. J. Org. Chem. 2007, 5250-5255.

[2] Concellón, J. M.; Suárez, J. R.; del Solar, V. Org. Lett. 2006, 8, 349-351.

[3] Baeza, A.; Casas, J.; Nájera, C.; Sansano, J. M. J. Org. Chem. 2006, 71, 3837-3848.

[4] Baeza, A.; Nájera, C.; Sansano, J. M.; Saá, J. M. *Chem. Eur. J.* **2005**, *11*, 3849-3862.

[5] Cresswell, A. J.; Davies, S. G.; Lee, J. A.; Morris, M. J.; Roberts, P. M.; Thomson, J.
E. J. Org. Chem. 2012, 77, 7262–7281.